List of benzodiazepines explained

The tables below contain a sample list of benzodiazepines and benzodiazepine analogs that are commonly prescribed, with their basic pharmacological characteristics, such as half-life and equivalent doses to other benzodiazepines, also listed, along with their trade names and primary uses. The elimination half-life is how long it takes for half of the drug to be eliminated by the body. "Time to peak" refers to when maximum levels of the drug in the blood occur after a given dose. Benzodiazepines generally share the same pharmacological properties, such as anxiolytic, sedative, hypnotic, skeletal muscle relaxant, amnesic, and anticonvulsant effects. Variation in potency of certain effects may exist amongst individual benzodiazepines. Some benzodiazepines produce active metabolites. Active metabolites are produced when a person's body metabolizes the drug into compounds that share a similar pharmacological profile to the parent compound and thus are relevant when calculating how long the pharmacological effects of a drug will last. Long-acting benzodiazepines with long-acting active metabolites, such as diazepam and chlordiazepoxide, are often prescribed for benzodiazepine or alcohol withdrawal as well as for anxiety if constant dose levels are required throughout the day. Shorter-acting benzodiazepines are often preferred for insomnia due to their lesser hangover effect.[1] [2] [3] [4] [5]

It is fairly important to note that elimination half-life of diazepam and chlordiazepoxide, as well as other long half-life benzodiazepines, is twice as long in the elderly compared to younger individuals. Due to increased sensitivity and potentially dangerous adverse events among elderly patients, it is recommended to avoid prescribing them as specified by the 2015 American Geriatrics Society Beers Criteria.[6] Individuals with an impaired liver also metabolize benzodiazepines more slowly. Thus, the approximate equivalent of doses below may need to be adjusted accordingly in individuals on short acting benzodiazepines who metabolize long-acting benzodiazepines more slowly and vice versa. The changes are most notable with long acting benzodiazepines as these are prone to significant accumulation in such individuals and can lead to withdrawal symptoms. For example, the equivalent dose of diazepam in an elderly individual on lorazepam may be half of what would be expected in a younger individual.[7] [8] Equivalent doses of benzodiazepines differ as much as 20 fold.[9] [10] [11]

Pharmacokinetic properties of various benzodiazepines

Equivalency data in the table below is taken from the Ashton "Benzodiazepine Equivalence Table".[4] [12] [13] [14]

data-sort-type="text" Drug Name Common Trade Namesdata-sort-type="number" Year ApprovedTypical Oral Dosage Formulations data-sort-type="number" Approx. Equivalent Oral Dose to 10 mg Diazepam data-sort-type="number" Peak Onset of Actiondata-sort-type="number" Elimination Half-life of Active Metabolite Primary Therapeutic Use
AdinazolamDeracyn1–23anxiolytic, antidepressant
AlprazolamXanax, Helex, Xanor, Trankimazin, Onax, Alprox, Misar, Restyl, Solanax, Tafil, Neurol, Frontin, Kalma, Ksalol, Farmapram0.25, 0.5, 1, 20.51–311-13 [10–20][15] anxiolytic, antidepressant[16]
BentazepamThiadipona251–32–4anxiolytic
Bretazenil[17] 2.5anxiolytic, anticonvulsant
BromazepamLexotanil, Lexotan, Lexilium, Lectopam, Lexaurin, Lexatin, Bromam1.5, 3, 661–520–40anxiolytic,hypnotic, muscle relaxant
Bromazolam2, 42anxiolytic
BrotizolamLendormin, Dormex, Sintonal, Noctilan0.250.50.5–24–5hypnotic
CamazepamAlbego, Limpidon401–36–11anxiolytic
ChlordiazepoxideLibrium, Risolid, Elenium5, 10, 25251.5–636–200anxiolytic
CinazepamLevana0.5, 1, 22–460hypnotic, anxiolytic
CinolazepamGerodorm400.5–29hypnotic
ClobazamOnfi, Frisium, Urbanol5, 10, 2020 1–58–60anxiolytic, anticonvulsant
ClonazepamRivatril, Rivotril, Klonopin, Iktorivil, Paxam0.5, 1, 20.5-11–519.5–50anticonvulsant, anxiolytic
Clonazolam0.25, 0.50.20.5-13-4[18] hypnotic, anticonvulsant
ClorazepateTranxene, Tranxilium3.75, 5, 7.515Variable32–152anxiolytic, anticonvulsant
ClotiazepamVeratran, Clozan, Rize5, 10101–34anxiolytic
CloxazolamCloxam, Sepazon, Olcadil1, 2, 41.5 2–555–77 anxiolytic, anticonvulsant
DelorazepamDadumir0.5, 1, 21-1.51–279<[19] anxiolytic, amnesic
Deschloroetizolam1, 24anxiolytic
DiazepamAntenex, Apaurin, Apzepam, Apozepam, Diazepan, Hexalid, Normabel, Pax, Stesolid, Stedon, Tranquirit, Valium, Vival, Valaxona2, 5, 10101–1.532–205anxiolytic, anticonvulsant, muscle relaxant, amnesic
Diclazepam[20] 1, 221.5–342 anxiolytic, muscle relaxant
EstazolamProSom, Nuctalon1, 22 3–510–24hypnotic, anxiolytic
Ethyl carfluzepate2 1–511–24hypnotic
EtizolamEtilaam, Etizest, Pasaden, Depas121–35-7anxiolytic, muscle relaxant, anticonvulsant
Ethyl loflazepateVictan, Meilax, Ronlax2[21] 2.5–373–119anxiolytic
Flualprazolam0.5, 10.25 1-212-22 anxiolytic, hypnotic
Flubromazepam[22] Templex4, 8, 1241.5–8100–220anxiolytic, hypnotic, amnesic, muscle relaxant, anticonvulsant
FlubromazolamRemnon0.25, 0.50.075 0.5-510-20[23] hypnotic
Fluclotizolam0.25-0.5 anxiolytic
FlunitrazepamRohypnol, Hipnosedon, Vulbegal, Fluscand, Flunipam, Ronal, Rohydorm, Hypnodorm1, 21.50.5–318–200hypnotic
Flunitrazolam0.25, 0.50.1 0.5-1 5-13 hypnotic
FlurazepamDalmadorm, Dalmane, Fluzepam30 20-251–1.540–250hypnotic
FlutazolamCoreminal4101-347-100hypnotic
Flutemazepam10.5-58-20hypnotic, anxiolytic, anticonvulsant, muscle relaxant[24]
FlutoprazepamRestas1, 22.50.5–987[25] hypnotic, anticonvulsant, muscle relaxant
HalazepamAlapryl, Paxipam20, 40403–615-35 [30-100]anxiolytic
KetazolamAnxon, Sedotime15, 30, 45202.5–630-100 [36-200]anxiolytic
LoprazolamDormonoct, Havlane1, 21.52–56–20[26] hypnotic
LorazepamAtivan, Orfidal, Lorenin, Lorsilan, Temesta, Tavor, Lorabenz0.5, 1, 2, 2.512–410–20anxiolytic, anticonvulsant, hypnotic, muscle relaxant[27] [28]
LormetazepamLoramet, Noctamid, Pronoctan1, 21.50.5–210-12hypnotic, anxiolytic
Meclonazepam6anxiolytic
MedazepamNobrium, Ansilan, Mezapam, Rudotel, Raporan10104-836–200anxiolytic
Metizolam1, 2, 42–412anxiolytic
MexazolamMelex, Sedoxil0.5, 11–2anxiolytic
MidazolamDormicum, Flormidal, Versed, Hypnovel, Dormonid7.5, 1510 (oral)4 (IV)0.5–11.8-6 hypnotic, anticonvulsant
Nifoxipam0.5, 1, 2hypnotic
NimetazepamErimin, Lavol52.5-50.5–314–30hypnotic
Nitemazepam2 0.5-5 10-27 hypnotic, anticonvulsant
NitrazepamMogadon, Alodorm, Pacisyn, Dumolid, Nitrazadon5, 1050.5–717–48hypnotic, anticonvulsant
Nitrazolam0.5, 1hypnotic
NordazepamMadar, Stilny5, 7.5, 1510-1530–150anxiolytic
Norflurazepam547-100hypnotic
OxazepamSeresta, Serax, Serenid, Serepax, Sobril, Oxabenz, Oxapax, Oxascand, Ox-Pam, Opamox, Alepam, Medopam, Murelax, Noripam, Purata10, 15, 30, 50303–44–11anxiolytic
PhenazepamPhenazepam, Phenzitat1.5–4 60anxiolytic, anticonvulsant
PinazepamDomar, Duna5, 1040–100anxiolytic
PrazepamDemetrin, Lysanxia, Prazene, Centrax10, 20, 3015-202–636–200anxiolytic
Premazepam152–610–13anxiolytic
Pyrazolam0.25, 0.5, 11–1.516–18[29] anxiolytic, amnesic
QuazepamDoral, Quiedorm15201–539–120hypnotic
RilmazafoneRhythmy11hypnotic
TemazepamRestoril, Normison, Euhypnos, Temaze, Tenox10, 2015-200.5–34–11hypnotic, anxiolytic, muscle relaxant
TetrazepamMyolastan, Clinoxam, Epsipam, Musaril501–33–26 muscle relaxant, anxiolytic
TriazolamHalcion, Rilamir, Notison, Somese0.125, 0.250.50.5–22hypnotic
Drug Name Common Trade Names Year Approved Typical Dosages of Oral TabletsApprox. Equivalent Oral Dose to 10mg Diazepam Peak onset of action Elimination Half-life of Active Metabolite Primary Therapeutic Use

Atypical benzodiazepine receptor ligands

Drug NameCommon Trade Names Year approved(US FDA) Elimination Half-lifeof Active Metabolite Primary Therapeutic Use
anxiogenic, convulsant
FlumazenilAnexate, Lanexat, Mazicon, Romazicon 1 antidote
Eszopiclone§ Lunesta 2004 6 hypnotic
Zaleplon§ Sonata, Starnoc 1999 1 hypnotic
Zolpidem§ Ambien, Nytamel, Sanval, Stilnoct, Stilnox, Sublinox (Canada), Xolnox, Zoldem, Zolnod 1992 2.6 hypnotic
Zopiclone§ Imovane, Rhovane, Ximovan; Zileze; Zimoclone; Zimovane; Zopitan; Zorclone, Zopiklone 4–6 hypnotic

Controversy

In 2015 the UK's House of Commons attempted to get a two to four week limit mandate for prescribing benzodiazepines to replace the two to four week benzodiazepine prescribing guidelines, which are merely recommended.[30]

Binding data and structure-activity relationship

A large number of benzodiazepine derivatives have been synthesised and their structure-activity relationships explored in detail.[31] [32] [33] [34] This chart contains binding data for benzodiazepines and related drugs investigated by Roche up to the late 1990s (though in some cases the compounds were originally synthesised by other companies such as Takeda or Upjohn).[35] [36] [37] [38] [39] [40] Other benzodiazepines are also listed for comparison purposes,[41] [42] [43] but it does not however include binding data for;

While binding or activity data are available for most of these compounds also, the assay conditions vary between sources, meaning that in many cases the values are not suitable for a direct comparison. Many older sources used animal measures of activity (i.e. sedation or anticonvulsant activity) but did not measure in vitro binding to benzodiazepine receptors.[49] [50] See for instance Table 2 vs Table 11 in the Chem Rev paper, Table 2 lists in vitro pIC50 values matching those below, while Table 11 has pEC50 values derived from in vivo assays in mice, which show the same activity trends but cannot be compared directly, and includes data for compounds such as diclazepam and flubromazepam which are not available in the main data set.

Also note;

See also

Further reading

Notes and References

  1. Golombok S, Lader M . The psychopharmacological effects of premazepam, diazepam and placebo in healthy human subjects . British Journal of Clinical Pharmacology . 18 . 2 . 127–133 . August 1984 . 6148956 . 1463527 . 10.1111/j.1365-2125.1984.tb02444.x .
  2. de Visser SJ, van der Post JP, de Waal PP, Cornet F, Cohen AF, van Gerven JM . Biomarkers for the effects of benzodiazepines in healthy volunteers . British Journal of Clinical Pharmacology . 55 . 1 . 39–50 . January 2003 . 12534639 . 1884188 . 10.1046/j.1365-2125.2002.t01-10-01714.x .
  3. Web site: Benzodiazepine Names . 2009-04-05 . non-benzodiazepines.org.uk . dead . https://web.archive.org/web/20081208054743/http://www.non-benzodiazepines.org.uk/benzodiazepine-names.html . 2008-12-08 .
  4. Web site: Ashton CH . Benzodiazepine Equivalence Table . benzo.org.uk . March 2007 . 2009-04-05.
  5. Web site: Hsiung R . Benzodiazepine Equivalence Charts . dr-bob.org . July 1995 . 2009-04-05 . dead . https://web.archive.org/web/20090209062022/http://www.dr-bob.org/tips/bzd.html . 2009-02-09 .
  6. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults . Journal of the American Geriatrics Society . 63 . 11 . 2227–2246 . November 2015 . 26446832 . 10.1111/jgs.13702 . American Geriatrics Society 2015 Beers Criteria Update Expert Panel . 38797655 . By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel . free .
  7. Book: Salzman C . Clinical geriatric psychopharmacology . 4th . 15 May 2004 . Lippincott Williams & Wilkins . USA . 978-0-7817-4380-8 . 450–453.
  8. Delcò F, Tchambaz L, Schlienger R, Drewe J, Krähenbühl S . Dose adjustment in patients with liver disease . Drug Safety . 28 . 6 . 529–545 . 2005 . 15924505 . 10.2165/00002018-200528060-00005 . 9849818 .
  9. Riss J, Cloyd J, Gates J, Collins S . Benzodiazepines in epilepsy: pharmacology and pharmacokinetics . Acta Neurologica Scandinavica . 118 . 2 . 69–86 . August 2008 . 18384456 . 10.1111/j.1600-0404.2008.01004.x . 24453988 . free .
  10. Ashton H . Guidelines for the rational use of benzodiazepines. When and what to use . Drugs . 48 . 1 . 25–40 . July 1994 . 7525193 . 10.2165/00003495-199448010-00004 . 46966796 .
  11. Web site: benzo.org.uk : Benzodiazepines: How They Work & How to Withdraw, Prof C H Ashton DM, FRCP, 2002. benzo.org.uk. 2019-12-19.
  12. Web site: Benzodiazepine Equivalence Chart . www.mental-health-today.com. https://web.archive.org/web/20230130205747/http://www.mental-health-today.com/rx/benzo.htm. 30 January 2023. dead.
  13. Web site: Benzodiazepine Equivalence Table . www.bcnc.org.uk . https://web.archive.org/web/20150206035118/http://www.bcnc.org.uk/equivalence.html . 2015-02-06 . April 2007.
  14. Farinde A . Benzodiazepine Equivalency Table . Medscape . 31 July 2018.
  15. Moylan S, Giorlando F, Nordfjærn T, Berk M . The role of alprazolam for the treatment of panic disorder in Australia . The Australian and New Zealand Journal of Psychiatry . 46 . 3 . 212–224 . March 2012 . 22391278 . 10.1177/0004867411432074 . 11006795 .
  16. Ashton Manual
  17. van Steveninck AL, Gieschke R, Schoemaker RC, Roncari G, Tuk B, Pieters MS, Breimer DD, Cohen AF . 6 . Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol . British Journal of Clinical Pharmacology . 41 . 6 . 565–573 . June 1996 . 8799523 . 2042631 . 10.1046/j.1365-2125.1996.38514.x .
  18. N. Edinoff . Amber . A. Nix . Catherine . S. Odisho . Amira . P. Babin . Caroline . G. Derouen . Alyssa . C. Lutfallah . Salim . M. Cornett . Elyse . Murnane . Kevin S. . M. Kaye . Adam . 22 August 2022 . Müller . Thomas . Yamauchi . Junji . Novel Designer Benzodiazepines: Comprehensive Review of Evolving Clinical and Adverse Effects . Neurology International . 14 . 3 . 652 . 10.3390/neurolint14030053 . 35997362. 9397074 . free .
  19. Web site: NMS Labs Report . NMS Labs . 19 April 2022.
  20. Moosmann B, Bisel P, Auwärter V . Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics . Drug Testing and Analysis . 6 . 7–8 . 757–763 . 2014 . 24604775 . 10.1002/dta.1628 .
  21. Web site: Benzodiazepine Names. 2009-05-31. non-benzodiazepines.org.uk. dead. https://web.archive.org/web/20081208054743/http://www.non-benzodiazepines.org.uk/benzodiazepine-names.html. 2008-12-08.
  22. Moosmann B, Huppertz LM, Hutter M, Buchwald A, Ferlaino S, Auwärter V . Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics . Journal of Mass Spectrometry . 48 . 11 . 1150–1159 . November 2013 . 24259203 . 10.1002/jms.3279 . 2013JMSp...48.1150M .
  23. Huppertz LM, Moosmann B, Auwärter V . Flubromazolam - Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine . Drug Testing and Analysis . 10 . 1 . 206–211 . January 2018 . 28378533 . 10.1002/dta.2203 .
  24. Esmailian M, Ahmadi O, Taheri M, Zamani M . Comparison of haloperidol and midazolam in restless management of patients referred to the Emergency Department: A double-blinded, randomized clinical trial . Journal of Research in Medical Sciences . 20 . 9 . 844–849 . September 2015 . 6486117 . 10.1002/14651858.CD003079.pub4 . 29219171 .
  25. Barzaghi N, Leone L, Monteleone M, Tomasini G, Perucca E . Pharmacokinetics of flutoprazepam, a novel benzodiazepine drug, in normal subjects . European Journal of Drug Metabolism and Pharmacokinetics . 14 . 4 . 293–298 . 1989 . 2633923 . 10.1007/BF03190114 . 20710732 .
  26. Swift CG, Swift MR, Ankier SI, Pidgen A, Robinson J . Single dose pharmacokinetics and pharmacodynamics of oral loprazolam in the elderly . British Journal of Clinical Pharmacology . 20 . 2 . 119–128 . August 1985 . 2864049 . 1400680 . 10.1111/j.1365-2125.1985.tb05041.x .
  27. Shah D, Borrensen D . Benzodiazepines: A Guide to Safe Prescribing . The Carlat Report: Psychiatry . 2011 . 2015-06-28 . 2015-07-01 . https://web.archive.org/web/20150701013255/http://www.thecarlatreport.com/sites/default/files/2011%20TCPR%20Benzo%20Table.pdf . dead .
  28. Web site: Comparison of Benzodiazepines . Vancouver Hospital Pharmaceutical Sciences .
  29. Web site: Moosmann B, Hutter M, Huppertz LM, Auwärter V . Characterization of the designer benzodiazepines pyrazolam and flubromazepam and study on their detectability in human serum and urine samples . 2014-11-05 . dead . https://web.archive.org/web/20141105130415/http://infoespai.org/MossmannDPHG2013.pdf . 2014-11-05 .
  30. Web site: APPG for Involuntary Tranquilliser Addiction . benzo.org.uk . 21 March 2015.
  31. Sternbach LH . The benzodiazepine story . Journal of Medicinal Chemistry . 22 . 1 . 1–7 . January 1979 . 34039 . 10.1021/jm00187a001 .
  32. Hadjipavlou-Litina D, Hansch C . 1994 . Quantitative structure-activity relationships of the benzodiazepines. a review and reevaluation . Chemical Reviews . 94 . 6. 1483–1505 . 10.1021/cr00030a002 .
  33. Edinoff AN, Nix CA, Odisho AS, Babin CP, Derouen AG, Lutfallah SC, Cornett EM, Murnane KS, Kaye AM, Kaye AD. Novel Designer Benzodiazepines: Comprehensive Review of Evolving Clinical and Adverse Effects. Neurol Int. 2022 Aug 22;14(3):648-663.
  34. Yu X, Greenblatt HK, Greenblatt DJ. Designer benzodiazepines: an update. Expert Rev Clin Pharmacol. 2023 Feb;16(2):109-117.
  35. Haefely W, Kyburz E, Gerecke M, Mohler H . 1985 . Recent advances in the molecular pharmacology of benzodiazepine receptors and in the structure-activity relationships of their agonists and antagonists . Adv. Drug Res . 1985 . 14. 165–322 .
  36. Winkler DA, Burden FR, Watkins AJ . Atomistic Topological Indices Applied to Benzodiazepines using Various Regression Methods . Quantitative Structure-Activity Relationships . January 1998 . 17 . 1 . 14–19 . 10.1002/(SICI)1521-3838(199801)17:01<14::AID-QSAR14>3.0.CO;2-U.
  37. Thakur A, Thakur M, Khadikar P . Topological modeling of benzodiazepine receptor binding . Bioorganic & Medicinal Chemistry . 11 . 23 . 5203–5207 . November 2003 . 14604684 . 10.1016/j.bmc.2003.08.014 .
  38. So SS, Karplus M . Genetic neural networks for quantitative structure-activity relationships: improvements and application of benzodiazepine affinity for benzodiazepine/GABAA receptors . Journal of Medicinal Chemistry . 39 . 26 . 5246–5256 . December 1996 . 8978853 . 10.1021/jm960536o .
  39. Book: Braestrup C, Nielsen M . Benzodiazepine receptors. Biochemical Studies of CNS Receptors . Iversen LL, Iversen SD, Snyder SH . Handbook of Psychopharmacology . 1983 . Springer . 9781468443615 .
  40. Book: Zhang W, Diaz-Arauzo H, Allen MS, Koehler KF, Cook JM . Chapter 7: Chemical and computer assisted development of the inclusive pharmacophore of benzodiazepine receptors. . Studies in Medicinal Chemistry . Choudhary MI . 1996 . 303 . CRC Press . 9783718658794 .
  41. Obradović AL, Joksimović S, Poe MM, Ramerstorfer J, Varagic Z, Namjoshi O, Batinić B, Radulović T, Marković B, Roth BL, Sieghart W, Cook JM, Savić MM . 6 . Sh-I-048A, an in vitro non-selective super-agonist at the benzodiazepine site of GABAA receptors: the approximated activation of receptor subtypes may explain behavioral effects . Brain Research . 1554 . 36–48 . March 2014 . 24472579 . 3996760 . 10.1016/j.brainres.2014.01.036 .
  42. Cornett EM, Novitch MB, Brunk AJ, Davidson KS, Menard BL, Urman RD, Kaye AD . New benzodiazepines for sedation . Best Practice & Research. Clinical Anaesthesiology . 32 . 2 . 149–164 . June 2018 . 30322456 . 10.1016/j.bpa.2018.06.007 . 53501694 .
  43. Clayton T, Poe MM, Rallapalli S, Biawat P, Savić MM, Rowlett JK, Gallos G, Emala CW, Kaczorowski CC, Stafford DC, Arnold LA, Cook JM . 6 . A Review of the Updated Pharmacophore for the Alpha 5 GABA(A) Benzodiazepine Receptor Model . International Journal of Medicinal Chemistry . 2015 . 430248 . 2015 . 26682068 . 4657098 . 10.1155/2015/430248 . free .
  44. Moosmann B, King LA, Auwärter V . Designer benzodiazepines: A new challenge . World Psychiatry . 14 . 2 . 248 . June 2015 . 26043347 . 4471986 . 10.1002/wps.20236 .
  45. Book: Moosmann B, Auwärter V . New Psychoactive Substances . Designer Benzodiazepines: Another Class of New Psychoactive Substances . Handbook of Experimental Pharmacology . 252 . 383–410 . 2018 . 30367253 . 10.1007/164_2018_154 . 978-3-030-10560-0 . Maurer H, Brandt S .
  46. Manchester KR, Lomas EC, Waters L, Dempsey FC, Maskell PD . The emergence of new psychoactive substance (NPS) benzodiazepines: A review . Drug Testing and Analysis . 10 . 1 . 37–53 . January 2018 . 28471096 . 10.1002/dta.2211 . free .
  47. Waters L, Manchester KR, Maskell PD, Haegeman C, Haider S . The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines . Science & Justice . 58 . 3 . 219–225 . May 2018 . 29685303 . 10.1016/j.scijus.2017.12.004 .
  48. Zawilska JB, Wojcieszak J . An expanding world of new psychoactive substances-designer benzodiazepines . Neurotoxicology . 73 . 8–16 . July 2019 . 30802466 . 10.1016/j.neuro.2019.02.015 . 73461430 .
  49. Blair T, Webb GA . Electronic factors in the structure-activity relationship of some 1,4-benzodiazepin-2-ones . Journal of Medicinal Chemistry . 20 . 9 . 1206–1210 . September 1977 . 926122 . 10.1021/jm00219a019 .
  50. Biagi GL, Barbaro AM, Guerra MC, Babbini M, Gaiardi M, Bartoletti M, Borea PA . Rm values and structure-activity relationship of benzodiazepines . Journal of Medicinal Chemistry . 23 . 2 . 193–201 . February 1980 . 7359533 . 10.1021/jm00176a016 .
  51. Catalani V, Floresta G, Botha M, Corkery JM, Guirguis A, Vento A, Abbate V, Schifano F. In silico studies on recreational drugs: 3D quantitative structure activity relationship prediction of classified and de novo designer benzodiazepines. Chem Biol Drug Des. 2023 Jan;101(1):40-51.
  52. Spencer J, Rathnam RP, Chowdhry BZ . 1,4-Benzodiazepin-2-ones in medicinal chemistry . Future Medicinal Chemistry . 2 . 9 . 1441–1449 . September 2010 . 21426139 . 10.4155/fmc.10.226 .